Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm
- PMID: 38653938
- DOI: 10.1007/s10787-024-01477-0
Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm
Abstract
Huntington's disease (HD) is an inherited, autosomal, neurodegenerative ailment that affects the striatum of the brain. Despite its debilitating effect on its patients, there is no proven cure for HD management as of yet. Neuroinflammation, excitotoxicity, and environmental factors have been reported to influence the regulation of gene expression by modifying epigenetic mechanisms. Aside focusing on the etiology, changes in epigenetic mechanisms have become a crucial factor influencing the interaction between HTT protein and epigenetically transcribed genes involved in neuroinflammation and HD. This review presents relevant literature on epigenetics with special emphasis on neuroinflammation and HD. It summarizes pertinent research on the role of neuroinflammation and post-translational modifications of chromatin, including DNA methylation, histone modification, and miRNAs. To achieve this about 1500 articles were reviewed via databases like PubMed, ScienceDirect, Google Scholar, and Web of Science. They were reduced to 534 using MeSH words like 'epigenetics, neuroinflammation, and HD' coupled with Boolean operators. Results indicated that major contributing factors to the development of HD such as mitochondrial dysfunction, excitotoxicity, neuroinflammation, and apoptosis are affected by epigenetic alterations. However, the association between neuroinflammation-altered epigenetics and the reported transcriptional changes in HD is unknown. Also, the link between epigenetically dysregulated genomic regions and specific DNA sequences suggests the likelihood that transcription factors, chromatin-remodeling proteins, and enzymes that affect gene expression are all disrupted simultaneously. Hence, therapies that target pathogenic pathways in HD, including neuroinflammation, transcriptional dysregulation, triplet instability, vesicle trafficking dysfunction, and protein degradation, need to be developed.
Keywords: DNA methyltransferase inhibitor; Epigenetic; Histone deacetylase inhibitor; Huntington’s disease; Post-translational modification; Transcriptional activation.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Epigenetics of Huntington's Disease.Adv Exp Med Biol. 2017;978:277-299. doi: 10.1007/978-3-319-53889-1_15. Adv Exp Med Biol. 2017. PMID: 28523552 Review.
-
DNA methylation in Huntington's disease: Implications for transgenerational effects.Neurosci Lett. 2016 Jun 20;625:34-9. doi: 10.1016/j.neulet.2015.10.060. Epub 2015 Nov 11. Neurosci Lett. 2016. PMID: 26522374 Free PMC article. Review.
-
Epigenetic regulation in Huntington's disease.Neurochem Int. 2021 Sep;148:105074. doi: 10.1016/j.neuint.2021.105074. Epub 2021 May 24. Neurochem Int. 2021. PMID: 34038804 Free PMC article. Review.
-
Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.J Huntingtons Dis. 2015;4(1):1-15. doi: 10.3233/JHD-159001. J Huntingtons Dis. 2015. PMID: 25813218 Review.
-
Epigenetic modifications as novel therapeutic targets for Huntington's disease.Epigenomics. 2014 Jun;6(3):287-97. doi: 10.2217/epi.14.19. Epigenomics. 2014. PMID: 25111483
References
Publication types
MeSH terms
LinkOut - more resources
Medical